Rockville Biotech Buys Rival's Anthrax Vaccine

The effort to protect the country from another anthrax attack will take an unexpected turn today when Rockville firm Emergent BioSolutions plans to announce that it has bought for $2 million an anthrax vaccine from a California company that federal health officials dropped in 2006.
 - 

Michael S. Rosenwald

Related Subjects

PharmAthene Inc.

Yale University

U.S. Department of Defense

California

Michigan

Midwestern States

Pacific States

San Mateo County

Medicine

Health and Fitness

Contagious and Infectious Diseases

Medical Treatments and Procedures

Vaccines

Anthrax

Stock Offerings

Stock Activity

Financial Markets

Business

Mergers and Acquisitions

Company Activities and Information

Powered by Inform

Related Articles

Emergent BioSolutions buys anthrax vaccine candidate BizJournals Health Care Portal 5/7/2008 11:16:22 AM

PharmAthene to Host First Quarter 2008 Conference Call and Webcast on Tuesday, May 13, 2008 Genetic Engineering News 5/6/2008 5:06:04 PM

VaxGen Sells Anthrax Vaccine Program and Related Assets and Technology to Emergent BioSolutions, Inc. Genetic Engineering News 5/6/2008 4:54:55 PM

Novavax Opens Infectious Disease Vaccine Plant in Maryland Genetic Engineering News 5/6/2008 4:24:37 PM

CDC Commissions Acambis for $425M to Supply Smallpox Vaccine Genetic Engineering News 5/6/2008 4:24:36 PM

Emergent BioSolutions Acquires Advanced Recombinant Protective Antigen Anthrax Vaccine Candidate and Technology Genetic Engineering News 5/6/2008 4:24:35 PM

VaxGen sells vaccine for anthrax to rival San Jose Mercury News 5/6/2008 10:08:06 AM

VaxGen sells anthrax vaccine rights for up to $10M BizJournals 5/5/2008 10:03:06 AM

PRESS DIGEST - Washington Post Business - May 5 Reuters 5/5/2008 1:07:27 AM

Novavax opens new plant for infectious disease vaccines Boston Globe 5/1/2008 1:45:36 PM

Powered by Inform